Ovarian Cancer Drugs Helps to Slow Down the Progression of the Cancer And Can Be Used With Chemotherapy
Ovarian Cancer Drugs |
There are some treatments available that involve different ovarian cancer
drugs for this condition. Chemotherapy is a standard form of ovarian cancer
treatment, usually involving two different types of drugs. Combination
therapies seem to be more effective than single-drug therapy. Patients
typically receive a platinum compound like carboplatin or olaparib, as well as
a taxane drug such as docetaxel or paclitaxel. It takes around three to four
weeks for the chemotherapy to start and the patient is given rest after the
first treatment.
Bevacizumab, known by its trade name Bevacizumab, is an immunotherapy drug
used as ovarian cancer drugs that helps shrink advanced epithelial ovarian
cancer. This treatment is best given along with chemotherapy, as it blocks the
genetic changes that promote tumor growth. It's also given as a maintenance
therapy for women with BRCA mutations and can be combined with chemotherapy to
achieve optimal results. It's administered as an IV every two to three weeks,
and has shown to be effective in suppressing tumor growth.
Parp inhibitors, such as olaparib are also ovarian cancer drugs that have
been used to slow the progression of ovarian cancer. Although they are not 100%
effective, the Ovarian
Cancer Drugs has shown promise in some trials. Several studies
have shown that PARP inhibitors have an overall survival rate of 93 percent.
These findings, however, are inconsistent. Some women do not respond to these
drugs, and researchers are looking for better ways to improve the chances that
PARP inhibitors are effective in treating the disease.
A small number of ovarian cancers have changes to the NTRK gene. These
cells produce proteins abnormally. Entrectinib and larotrectinib are two such
drugs. Both are prescribed to women with advanced ovarian cancer. They are
taken as pills, usually once or twice a day, and the side effects are minor.
Although they are deemed mild, they can cause dizziness, fatigue, and
constipation. Occasionally, patients will experience weight gain. In November
2021, The U.S. Food and Drug Administration (FDA) granted approval to Cytalux
(pafolacianine) an imaging drug designed for assisting surgeons in detecting
ovarian cancer lesions.
Comments
Post a Comment